View Older Stories View More Recent Stories

Dec 21, 2020 07:00AM ADDING MULTIMEDIA TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer
Dec 12, 2020 09:24AM AstraZeneca (AZN) to Acquire Alexion Pharma (ALXN) for $39B, or $175/Share
Dec 12, 2020 07:48AM AstraZeneca to Acquire Alexion, Accelerating the Company's Strategic and Financial Development
Dec 10, 2020 07:05AM AstraZeneca (AZN) Announces ENHERTU Continues to Demonstrate Durable Responses with New Data From DESTINY-Breast01 in HER2-positive Metastatic Breast Cancer
Dec 10, 2020 07:00AM ENHERTU (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Durable Responses with New Data From DESTINY-Breast01 in HER2-positive Metastatic Breast Cancer
Dec 7, 2020 10:00AM CALQUENCE Data Across Four Trials Reinforces Cardiovascular Safety Profile in Patients With Chronic Lymphocytic Leukemia
Dec 6, 2020 10:00AM CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma
Dec 6, 2020 10:00AM CORRECTING and REPLACING CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma
Dec 3, 2020 07:08AM AstraZeneca (AZN) Demonstrates Growing Leadership in Breast Cancer at SABCS with Data From Its Innovative Medicines and Robust Pipeline
Dec 3, 2020 07:00AM AstraZeneca Demonstrates Growing Leadership in Breast Cancer at SABCS with Data From Its Innovative Medicines and Robust Pipeline
Nov 20, 2020 07:02AM AstraZeneca (AZN) Announces IMFINZI Approved In The US For Less-Frequent, Fixed-Dose Use
Nov 20, 2020 07:00AM IMFINZI® (durvalumab) Approved In The US For Less-Frequent, Fixed-Dose Use
Nov 19, 2020 07:00AM AstraZeneca Demonstrates Strength in Hematology With Robust Data at ASH 2020
Nov 16, 2020 11:21AM Exclusive: EU eyes COVID vaccine deal with Moderna at less than $25 per dose, says source
Nov 13, 2020 10:00AM Data from contemporary registry confirms that four out of five patients with heart failure with reduced ejection fraction eligible for treatment with FARXIGA
Nov 10, 2020 07:00AM Tezepelumab NAVIGATOR Phase III Trial Met Primary Endpoint of a Statistically Significant and Clinically Meaningful Reduction in Exacerbations in a Broad Population of Patients With Severe Asthma
Nov 9, 2020 07:00AM Foundation Medicine Expands Indication for FoundationOne®Liquid CDx to be used as a Companion Diagnostic for LYNPARZA®
Nov 6, 2020 07:00AM BRILINTA Approved in the US to Reduce the Risk of Stroke in Patients With an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
Nov 2, 2020 07:08AM Fusion Pharma (FUSN) Announces Collaboration with AstraZeneca (AZN) to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies
Nov 2, 2020 07:00AM Fusion Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies
Oct 29, 2020 07:00AM FASENRA® eliminated oral corticosteroid use in a majority of OCS-dependent patients with asthma in PONENTE Phase IIIb trial
Oct 28, 2020 07:20AM AstraZeneca (AZN) Announces ENHERTU Granted Priority Review in US For Treatment of HER2-positive Metastatic Gastric Cancer
Oct 28, 2020 07:00AM ENHERTU (fam-trastuzumab deruxtecan-nxki) Granted Priority Review in the US For the Treatment of HER2-positive Metastatic Gastric Cancer
Oct 23, 2020 10:42AM AstraZeneca (AZN) Announces FARXIGA DAPA-CKD Phase III Trial Reduced Worsening of Kidney Function, Risk of Cardiovascular or Renal Death in Patients With CKD
Oct 23, 2020 10:40AM FARXIGA DAPA-CKD Phase III Trial Reduced Worsening of Kidney Function, Risk of Cardiovascular or Renal Death in Patients With Chronic Kidney Disease Irrespective of Underlying Cause
Oct 22, 2020 09:00AM AstraZeneca Announces Winners and Recognizes Unsung Heroes of Oncology in 2020 Cancer Community (C2) Awards
Oct 20, 2020 08:01AM TAGRISSO Granted Priority Review in the US for the Adjuvant Treatment of Patients With Early-stage EGFR-mutated Lung Cancer
Oct 9, 2020 04:50PM U.S. signs agreement with AstraZeneca to develop, supply COVID-19 antibody treatment
Oct 2, 2020 07:00AM FARXIGA Granted Breakthrough Therapy Designation in US for Chronic Kidney Disease
Sep 21, 2020 06:47AM AstraZeneca (AZN) and Merck (MRK) Announce LYNPARZA Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 mCRPC
Sep 20, 2020 12:30PM LYNPARZA® (olaparib) Reduced the Risk of Death by 31% in BRCA1/2 or ATM-mutated Metastatic Castration-Resistant Prostate Cancer in Phase III Profound Trial
Sep 19, 2020 01:04PM TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer
Sep 18, 2020 07:00AM IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Non-small Cell Lung Cancer With an Estimated 50% of Patients Surviving Four Years
Sep 18, 2020 07:00AM LYNPARZA® (olaparib) Improved Median Time Patients Lived Without Disease Progression to Over Four and Half Years in BRCA-mutated Advanced Ovarian Cancer vs. Just Over One Year With Placebo
Sep 18, 2020 06:46AM AstraZeneca (AZN), Merck (MRK) Report LYNPARZA Improved Median PFS to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with BRCA-Mutated Advanced Ovarian Cancer
Sep 15, 2020 07:03AM AstraZeneca Selects Veeva Vault Quality Suite to Modernize Global Quality Management
Sep 15, 2020 07:03AM AstraZeneca Selects Veeva Vault Quality Suite to Modernize Global Quality Management
Sep 8, 2020 06:31AM Vaccine makers announce pledge, outlining united commitment to uphold integrity of scientific process
Sep 8, 2020 06:31AM Biopharma Leaders Unite to Stand With Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite To Stand With Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite to Stand with Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite to Stand with Science
Aug 31, 2020 04:55PM AstraZeneca (AZN) Announces Development of COVID-19 Vaccine AZD1222 Expands Into US Phase III Clinical Trial Across All Adult Age Groups
Aug 31, 2020 04:53PM Development of COVID-19 Vaccine AZD1222 Expands Into US Phase III Clinical Trial Across All Adult Age Groups
Aug 31, 2020 06:07AM AstraZeneca (AZN) Reports Phase III DAPA-CKD Trial Shows Risk Reduction of Kidney Failure & Cardiovascular or Renal Death in Patients with Chronic Kidney Disease in
Aug 30, 2020 11:02AM FARXIGA Demonstrated Unprecedented Reduction in the Risk of Kidney Failure and Cardiovascular or Renal Death in Patients with Chronic Kidney Disease in the Phase III DAPA-CKD Trial
Aug 23, 2020 02:00PM Trump hails FDA's authorization of plasma treatment for coronavirus, after slamming agency
Aug 13, 2020 07:33AM AstraZeneca (AZN) Ships FLUMIST QUADRIVALENT Vaccine in the US for 2020-2021 Flu Season
Aug 13, 2020 07:30AM AstraZeneca Ships FLUMIST® QUADRIVALENT Vaccine in the US for 2020-2021 Flu Season
Aug 11, 2020 07:30AM AstraZeneca Partners with Actor and Author Tony Hale to Build Awareness of Eosinophilic Asthma and How Not All Asthma is the Same
View More Recent Stories View Older Stories